DarshanTalks Podcast

Send us Fan Mail

Edye Edens discusses what it truly means to be site audit ready and dispels the misconception that it requires 100% compliance. No auditor expects perfection—what matters is having strong processes in place to catch and address issues in real time, particularly those with safety or regulatory implications.

Being audit-ready means having the infrastructure to identify whether mistakes are isolated incidents or part of a larger trend requiring corrective action. Just like building credit requires a history of responsible transactions, regulatory credibility comes from demonstrating the ability to detect and resolve compliance issues effectively.

Rather than aiming for unattainable perfection, sites should focus on maintaining a proactive compliance system that ensures high-risk issues are caught early and addressed. 

If you need guidance on achieving true audit readiness, KLF is here to help.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

Citizen biohacking is an empowering movement where individuals take medical innovation into their own hands, often stepping in when traditional medicine falls short. Driven by necessity, love, and a desire for survival, many have solved complex medical problems themselves, leading to groundbreaking discoveries. This trend raises important questions about safety, ethics, and the future of healthcare, with both promise and complexity.

One of the most well-known examples is Lorenzo’s Oil, where Michaela and Augusto Odone developed a treatment for their son Lorenzo, who was diagnosed with a rare and fatal genetic disorder. Their research and persistence led to a groundbreaking treatment that helped slow the disease's progression. Another inspiring story is that of Dr. David Fajgenbaum, who, after being diagnosed with Castleman’s disease, repurposed existing drugs to stabilize his condition, saving his life and offering hope to others. These remarkable examples demonstrate how determination and innovation can lead to life-saving breakthroughs.

However, citizen biohacking raises crucial concerns, such as safety and ethics. Operating outside the traditional medical system, it challenges regulatory bodies to reconsider how innovation is validated and tested. Despite these challenges, citizen biohacking is changing the landscape of medicine, pushing the medical community to think differently, adapt more quickly, and collaborate with unconventional innovators. If you’re interested in exploring these stories and the legal implications of this trend, tune in to our Darshan Talks podcast or reach out to Kulkarni Law Firm for expert guidance. 

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

Mergers and Acquisitions (M&A) in the healthcare sector can be highly profitable, but they carry significant legal risks, particularly for private equity investors and board members who hold excessive influence over operations. The case of US XRL Martino Fleming vs. South Bay Mental Health Centers serves as a cautionary tale, highlighting how overstepping operational boundaries can lead to False Claims Act (FCA) violations. Investors, eager to enhance efficiency and profitability, may inadvertently trigger scrutiny by imposing aggressive performance targets or controlling daily operations, which could cross the line into operational control. In this case, allegations of fraudulent billing practices arose due to the investor’s involvement in clinical and administrative operations. Such claims can result in severe financial penalties and irreparable damage to reputation, affecting future investment opportunities.

The key takeaway here is that undue influence by investors can unintentionally create compliance liabilities. It is crucial for private equity firms to maintain a balance between oversight and operational independence. As part of M&A due diligence, integrating compliance reviews is essential. The Department of Justice (DOJ) issued updated guidance in 2023 and 2024, emphasizing the need for these reviews to focus on federal healthcare program regulations. This includes everything from Medicare billing practices to compliance with the Stark Law and Anti-Kickback Statute. Investors must conduct operational audits, understand the limits of control in regulated industries, and set up post-acquisition compliance frameworks to avoid liability. Ultimately, proactive compliance strategies are crucial to safeguarding against FCA violations and ensuring M&A transactions remain successful. Reach out to the Kulkarni Law Firm for tailored legal guidance and subscribe to the DarshanTalks Podcast for more insights into healthcare M&A best practices.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

Edye Edens from KLF highlights the key differences between sponsor-to-organization agreements and direct investigator agreements. Larger research organizations and academic medical centers often prefer sponsor-to-organization agreements because they provide structured negotiations around intellectual property (IP) rights, indirect costs, liability protections, and compliance oversight. These agreements also ensure that investigators have access to institutional resources and support.

On the other hand, direct investigator agreements may offer a faster turnaround, but they come with greater risks. Investigators negotiating independently might agree to terms that organizations would typically reject, potentially exposing themselves to legal and financial liabilities.

Understanding these distinctions is crucial for managing risk. While direct agreements may have their place, it’s essential to carefully evaluate the terms and ensure adequate protections. If you're unsure about the best approach for your situation, consult legal experts before signing. Need guidance? Get in touch with KLF.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

Most clinical trial site mergers focus on patient databases, sponsor contracts, and geographic expansion. While those are important, the real risks lie elsewhere—buried in compliance issues that can derail your deal before it even closes. Imagine acquiring a site that looks great on paper, only to face FDA or DOJ scrutiny months later due to undisclosed 483s, protocol deviations, or even kickback violations. Instead of scaling operations, you're dealing with regulatory investigations and potential fraud issues.

These risks are avoidable—if you know where to look. Before merging clinical trial sites, conduct thorough due diligence:
 1. IRB Approvals and Regulatory Compliance History – Review IRB approvals and study regulatory compliance history.

2. 483s and FDA warning letters- Review past 483s, and FDA warning letters.

3. IRB approvals- Ensure that all ongoing studies have IRB approvals.

4. Ensure Past Deviations & Adverse Events Are Resolved – Review all protocol deviations and adverse event reports to confirm they have been properly addressed. Compliance violations don’t disappear after a merger—they become your responsibility.

5.  Site Contracts & Investigator Agreements – Ensure contracts transfer post-merger and aren’t tied to individual physicians.

6. Verify Financial Disclosure Reporting – Ensure all financial disclosures are accurate and complete to avoid undisclosed conflicts of interest post-merger. 

7. Clinical Staff & Oversight – Verify investigator credentials, GCP training, and past compliance violations.

8. Verify PI Credentials – Confirm that the Principal Investigator’s credentials, licenses, and certifications are valid and up to date. 

9. Confirm GCP Training Compliance – Ensure all investigators have completed the required Good Clinical Practice (GCP) training.

10. Review Investigator-Specific Protocol Violations – Identify any past protocol violations linked to individual investigators. 

11. Assess Payment Structures & Financial Arrangements – Review whether payments are percentage-based or fee-for-service, and check for any financial perks like free rent.

12. Data Integrity & Patient Safety – Look for missing consent forms, protocol adherence issues, and any history of data fabrication.

13. Verify Informed Consent Documentation – Ensure all informed consent forms are properly documented and complete.

14. Review Protocol Adherence Records – Verify that the site consistently follows approved protocols.

Hidden compliance risks don’t disappear after a merger—they become your problem. The Kulkarni Law Firm helps clinical research sites, CROs, and investors identify and mitigate these risks before closing a deal. Contact us to safeguard your next clinical trial site merger.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

In this episode, Darshan Kulkarni sits down with Raymond Nomizu, founder and co-CEO of CRIO, to discuss key takeaways from the SOS conference and the evolving landscape of clinical research.

Raymond shares his journey from running a clinical research site to founding CRIO, a platform designed to modernize site operations through eSource, CTMS, and real-time data solutions. They explore major industry trends, including the rise of site networks, increasing sponsor demand for real-time data access, and the shifting role of decentralized clinical trials (DCTs).

They also discuss whether DCTs are truly revolutionizing research or simply becoming part of standard clinical operations. Raymond emphasizes that while centralization can improve efficiency in areas like finance, data management, and regulatory processes, the investigator-patient relationship must remain localized for research to be effective.

The SOS conference highlighted these ongoing shifts, and the conversation dives into how sites can stay competitive by adapting to sponsor expectations, leveraging technology, and optimizing operations.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

Darshan talks about a major blind spot in food M&A—hidden compliance risks that can destroy a deal overnight. While most focus on financials, market share, and synergies, they fail to account for regulatory pitfalls that can trigger investigations, recalls, or severe penalties. Imagine being deep in negotiations, only to discover unapproved ingredients, misleading health claims, or an undisclosed FDA warning letter buried in company files. Some executives make the mistake of pushing forward, thinking they’ll fix it later—but regulators like the FDA, USDA, and FTC won’t wait.

Many assume their internal legal teams can handle compliance due diligence, but food regulations are complex, spanning labeling, safety, advertising, and state consumer protection laws. The Kulkarni Law Firm specializes in identifying and resolving these risks before they become deal-breakers. We help buyers conduct regulatory due diligence, engage with federal and state regulators, assess liability risks in labeling and advertising, and structure compliance-driven transactions.

If you're involved in food M&A, don’t let compliance issues turn your investment into a liability. Reach out to the Kulkarni Law Firm to protect your deal and ensure regulatory success.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

The recent $47 million settlement involving QOL Medical and its CEO is a stark reminder of the consequences of crossing legal and ethical boundaries. Allegations of offering free Carbon 13 breath test kits as kickbacks to induce prescriptions for Sucraid, a treatment for congenital sucrose isomaltase deficiency (CSID), aren't just about non-compliance—they’re about patient safety. The breath tests could not specifically diagnose CSID but were marketed as such, leading to inappropriate prescriptions and fraudulent claims submitted to federal healthcare programs. This not only wasted resources but also put vulnerable patients at risk.

For those in the rare disease treatment space, this case highlights the need for transparency and truth in marketing. Ask yourself: Are your promotional strategies truthful? Are you offering incentives that could be misconstrued as kickbacks? In a field with limited data and high stakes, misleading marketing can erode trust, tarnish reputations, and invite legal scrutiny. Compliance is not just a checkbox—it’s a commitment to ethical practices that prioritize patient well-being. As you navigate these challenges, ensure your marketing practices are compliant while effectively educating healthcare providers about rare disease treatments. QOL Medical’s costly misstep should serve as a warning. 

For guidance on staying compliant, reach out to the Kulkarni Law Firm and learn how we can help.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

Edye Edens from KLF offers a brief yet in-depth overview of FDA regulatory submissions for clinical research in the U.S., reflecting on both current practices and predictions for 2025. She highlights how AI tools and evolving political dynamics are shaping the regulatory landscape, emphasizing that while efficiency improvements are necessary, careful and strategic approaches are critical to maintain the FDA’s global reputation and safety standards.

Edye discusses the complexity of submissions like Investigational New Drug (IND) and Investigational Device Exemption (IDE) applications, noting the significant preclinical work, detailed documentation, and thorough FDA review process involved. She also underscores the global weight of FDA approvals, as many international regulatory bodies rely on FDA assessments as a benchmark.

Finally, Edye poses key questions to her audience:

• How familiar are you with regulatory submissions?
• Are you considering outsourcing this complicated process?
• Where do you see opportunities for efficiency—through AI, technology, or administrative changes?
• If you’ve been a reviewer, how do you balance efficiency with safety?

Reach out for more info!

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

Carly Schaechter  discusses the potential of VR in drug promotion and the challenges of reviewing VR content for the PRC. Key points include the need for VR expertise to conceptualize interactive, engaging content. Choosing VR over AR depends on the objectives, with VR offering more controlled environments. Ensuring user control, addressing misinformation, and learning from past mistakes are crucial for successful VR implementation. Gamification and user experience evaluation are critical elements of the review process.

Support the show

www.kulkarnilawfirm.com